Health-related quality-of-life after transapical transcatheter aortic valve implantation

Figures & data

Figure 1. Patient flowchart. Flowchart displaying the total number of patients screened for eligibility, the number of eligible patients, and the patients included in the study. One patient withdrew consent prior to intervention and was not included in data analyses. TA-TAVI: transapical transcatheter aortic valve implantation; SAVR: surgical aortic valve replacement.

Table 1. Baseline characteristics of patients undergoing transapical transcatheter aortic valve implantation or surgical aortic valve replacement.

	TA-TAVI n = 29	SAVR n = 29
Age (years)	80 ± 4	82 ± 5
BMI (kg/m^2)	27 ± 5	25 ± 3
Male sex, n (%)	8 (28)	9 (31)
Diabetes, n (%)	0 (0)	3 (10)
Hypertension, n (%)	23 (79)	21 (72)
COPD, n (%)	1 (3)	3 (10)
Hypercholesterolemia, n (%)	16 (55)	17 (59)
Creatinine (μmol/l)	92 ± 54	88 ± 24
Ejection Fraction (%)	56 ± 2	57 ± 2
Aortic valve area (cm^2)	0.7 ± 0.2	0.7 ± 0.2
Peak gradient (mmHg)	80 ± 5	66 ± 5
Logistic EuroSCORE (%)	8.8 ± 0.8	9.9 ± 0.7
STS score (%)	3.2 ± 0.3	3.5 ± 0.2

Intention-to-treat data reported as means ± standard deviations or absolute numbers and percentages of patients.

TA-TAVI: transapical transcatheter aortic valve implantation; SAVR: surgical aortic valve replacement; BMI: body mass index; COPD: chronic obstructive pulmonary disease; STS: The Society of Thoracic Surgeons’ risk model predicting the risk of operative mortality after adult cardiac surgery.

Figure 2. Quality-of life (SF-36). Graphical description of quality-of life (SF-36) divided in physical composite summary (A) and mental composite summary (B) during 5 years of follow-up in patients undergoing TA-TAVI (n = 29) or SAVR (n = 29). Horizontal lines indicate standard deviations. TA-TAVI: transapical transcatheter aortic valve implantation; SAVR: surgical aortic valve replacement.

Table 2. Quality-of life (SF-36) in patients undergoing transapical transcatheter aortic valve implantation or surgical aortic valve replacement during 5 years of follow-up.

	TA-TAVI n = 29	SAVR n = 29	p-Value
Composite physical score (norm-based score)
Baseline	34 ± 10	37 ± 12	.37
1 year	44 ± 9	36 ± 9	.03
2 years	41 ± 11	39 ± 6	.60
3 years	41 ± 16	36 ± 9	.28
4 years	40 ± 8	39 ± 10	.80
5 years	37 ± 10	42 ± 10	.33
Composite mental score (norm-based score)
Baseline	46 ± 12	44 ± 18	.65
1 years	53 ± 10	48 ± 15	.37
2 years	53 ± 8	46 ± 14	.12
3 years	52 ± 8	49 ± 12	.45
4 years	52 ± 10	49 ± 12	.43
5 years	49 ± 12	44 ± 11	.35

Intention-to-treat data reported as means ± standard deviations.

TA-TAVI: transapical transcatheter aortic valve implantation; SAVR: surgical aortic valve replacement.

Table 3. Quality-of life (SF-36) in patients undergoing transapical transcatheter aortic valve implantation or surgical aortic valve replacement after 5 years of follow-up.

	TA-TAVI (n = 29)	SAVR (n = 29)	p-Value
SF-36 dimensions (norm-based score)
Physical functioning	55 (5–100)	58 (10–80)	.84
Role physical	50 (0–100)	50 (0–100)	.58
Bodily pain	72 (21–100)	80 (31–100)	.36
General health	69 (32–97)	61 (42–77)	.63
Vitality	58 (10–90)	53 (20–80)	.51
Social functioning	88 (25–100)	88 (38–100)	.90
Role emotional	67 (0–100)	67 (0–100)	.63
Mental health	82 (48–100)	62.5 (40–100)	.18

Intention-to-treat data reported as medians with total ranges.

TA-TAVI: transapical transcatheter aortic valve implantation; SAVR: surgical aortic valve replacement.